Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 16/20 | 0.44 |
| ▸ | CA2 | P00918 | 16/20 | 0.44 |
| ▸ | CA9 | Q16790 | 15/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA7 | P43166 | 5/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.42 |
| ▸ | CA3 | P07451 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA6 | P23280 | 4/20 | 0.42 |
| ▸ | CA5A | P35218 | 4/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28738004 | 0.93 | TSHR (0.63) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL5984526 | 0.93 | — | — | |
| SCHEMBL222525 | 0.82 | — | — | |
| Lithium Ion SCHEMBL17456418 | 0.82 | RECQL (0.65) | TSHRRECQLMAPK1GLAHPGD | |
| Lithium Ion SCHEMBL17456492 | 0.79 | RECQL (0.70) | TSHRRECQLMAPK1GLAHPGD | |
| Lithium Ion SCHEMBL17456412 | 0.79 | RECQL (0.70) | TSHRRECQLMAPK1GLAHPGD | |
| Ethylenediamine SCHEMBL21296506 | 0.79 | RECQL (0.88) | TSHRRECQLMAPK1GLAHPGD | |
| SCHEMBL9161783 | 0.77 | — | — | |
| SCHEMBL700982 | 0.77 | CA1 (0.50) | TSHRCA1CA2CA9CA12 | |
| SCHEMBL2750585 | 0.76 | RECQL (0.65) | TSHRRECQLMAPK1GLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4652621-A | MALEIMIDE WITH SULFONATE OR SULFATE GROUP, DRILLING FLUID DISPERSANT | NIPPON ZEON CO., LTD. (JP) | 1987-03-24 | — | — | US | claimed |
| EP-1691780-A2 | GENE DELIVERY MEDIATED BY LIPOSOME-DNA COMPLEX WITH CLEAVABLE PEG SURFACE MODIFICATION | ALZA CORPORATION (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005051351-A2 | GENE DELIVERY MEDIATED BY LIPOSOME-DNA COMPLEX WITH CLEAVABLE PEG SURFACE MODIFICATION | ALZA CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-6849270-B2 | Releasable linkage and compositions containing same | ALZA CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1465599-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030211079-A1 | Releasable linkage and compositions containing same | ALZA CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2003053409-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1173221-A2 | RELEASABLE LINKAGE AND COMPOSITIONS CONTAINING SAME | Alza Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064483-A2 | RELEASABLE LINKAGE AND COMPOSITIONS CONTAINING SAME | ALZA CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
| US-4652621-A | MALEIMIDE WITH SULFONATE OR SULFATE GROUP, DRILLING FLUID DISPERSANT | NIPPON ZEON CO., LTD. (JP) | 1987-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211079-A1 | Releasable linkage and compositions containing same | CD44, ILK, CD69 | TSHR 3735/4885RECQL 411/4885MAPK1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.